Über dich

There are conflicting results in the literature as to whether testosterone therapy has a significant impact on these symptoms. Men who seek medical care for possible testosterone therapy often present with non-specific symptoms, such as low energy and fatigue, which can be manifestations of other conditions, such as chronic stress, chronic fatigue, and depression. The rate of remission was also higher in a statistically significant manner among dysthymic men receiving testosterone therapy (53%) compared to placebo (19%).317, 318
The best time to obtain monitoring blood tests for IM testosterone has not been definitively established. The optimal dosing strategy has not been defined for short-acting IM testosterone preparations. Mean testosterone values over a 7-day time period were 1,659, 896, and 422 ng/dL for IM testosterone SQ 100, and SQ 50, respectively. The half-life for IM testosterone was also shorter at 173 hours versus 240 hours for SQ testosterone. Injectable testosterone is available in several forms, including short acting and long-acting preparations. In the clinical trial leading to FDA approval, side effects related to nasal delivery included nasopharyngitis, rhinorrhea, and epistaxis occurring in 7-10% of men.436
Scialli Consulting LLC did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Scialli Consulting LLC has no employees and did not support this study with either salary or any other funding. In 2012, sales for testosterone therapies exceeded $2 billion, and sales continue to grow in dozens of countries. However, the direction of causality is unclear; it is possible that obesity or lack of exercise and chronic disease lower testosterone rather than low testosterone concentrations causing disease.
Early morning samples from each subject\'s most recent and previous 3 visits as well as those from 10, 15, 20, 25, and 30 years prior were analyzed (3,565 samples total with a mean of 4 samples per patient). To merely refer to injectable or gel testosterone formulations without differentiation does not impart complete and accurate information to the reader. Finally, testosterone pellets are also available in branded form, with no generic agents currently available. For example, there are several testosterone gels available in 1%, 1.62%, and 2% formulations, each marketed under a different brand or generic name. While all products contain the same medication (testosterone), each product and modality has distinct pharmacokinetic and application attributes based on the excipient agents and the permeator components.
The target levels suggested here are physiological (eugonadal) not supraphysiological levels, and the Panel found no data to support the argument for dose escalation into the supraphysiological range in the pursuit of greater efficacy. Increases in testosterone for patients who lose weight might be cumulative over time. One RCT by Maggi et al. followed 715 testosterone deficient men for 12 weeks to evaluate the effects of a 2% transdermal testosterone agent on sex drive and energy. All patients had PSA and digital rectal exams every three months and biopsies annually. Six patients experienced biochemical recurrence, all of whom had intermediate- or high-risk prostate cancer. If the testosterone concentration is increased further, rather than further proliferation, the cells reduce their rate of proliferation.343, 344 This phenomenon is known as the bipolar testosterone concept. However, the saturation model introduced by Morgentaler is based on the concept that prostate cancer cells\' response to the testosterone level to which they are exposed is not linear in nature.
Unfavorable changes were reported in 2 studies 5, 25 and included increases in total cholesterol, LDL cholesterol, and triglycerides and decreases in HDL cholesterol in men evaluated as hypogonadal prior to androgen therapy. Favorable effects in 11 studies included 5–11% decreases in total cholesterol concentration and variable and inconsistent decreases in triglycerides and low-density lipoprotein (LDL) cholesterol. Serum or plasma concentrations of cholesterol fractions, triglycerides, and lipoproteins have been used as surrogate endpoints for cardiovascular risk, although they should not be mistaken for markers of cardiovascular adverse events. The improvements in exercise function appeared attributable to the response of men with baseline plasma testosterone concentration 23 Another study showed no effect of IM testosterone enanthate on ejection fraction, although there was an improvement in a Doppler-based myocardial performance index. Intramuscular (IM) testosterone treatment for 12 weeks improved exercise capacity and reduced heart failure symptom scores without identifiable effects on left ventricular size or ejection fraction (EF). There was a decreased incidence of silent MI with testosterone treatment in 1 study. The remaining eight studies evaluated treatments of 2 to 24 weeks in duration.1, 3, 10, 11, 13–17 The 3 studies that looked at time to ST-segment depression found a benefit of testosterone supplementation.1, 14, 16|Most authors with an interest in 17β-estradiol have suggested that the effectiveness of testosterone, when it has shown effectiveness, is due to aromatization to 17β-estradiol. Treatment of men with suspected or diagnosed Alzheimer disease or cognitive impairment was reported in five studies, two of which had a Jadad score above 3. Another injection study found no effect of supplementation on memory in hypogonadal men. The response of depression and dysthymia to testosterone was mixed and inconsistent. The study that used hostility assessments by undergraduate judges found no change in personality as assessed by the Gough and Heilbrun Adjective Check List. Twenty-nine of these studies focused on men without psychiatric disorders, and 16 on men with psychiatric disorders.|There are parallels between the recommendation of testosterone and of menopausal hormone therapy in women. It is also possible that another mechanism both lowers testosterone concentrations and increases the risk of some diseases. Testosterone treatment has been considered for disease prevention because men who are obese, diabetic, hypertensive, or chronically ill have lower plasma concentrations of testosterone.|To accurately interpret the published testosterone literature, it is important to critically evaluate various aspects of study design, including the population evaluated, study inclusion/exclusion criteria, duration of follow-up, primary endpoints, adverse event reporting, statistical reporting, and clinical relevance of findings. This is further complicated by laboratory methodology issues, such as time of day for the blood draws analyzed, number of levels checked, and assays used. An exception can be made if patients do not have symptoms but have documented BMD loss. Please refer to Table 7 below for a summary of follow-up testing for men being treated for testosterone deficiency. Patients on short-acting IM or short-acting SQ pellets (testosterone cypionate or enanthate) should have their testosterone measured after several cycles such that testosterone level equilibration has been achieved. Patients on topical gels, patches, and intranasal formulations should have their testosterone checked between two to four weeks after commencement of therapy. + FDA approved for use in males with hypogonadotropic hypogonadism and pediatric patients with cryptorchidism.|Clinicians should be aware that symptomatic gynecomastia or other breast symptoms are an uncommon side effect in men on testosterone therapy. The validation studies for each questionnaire use a distinct total testosterone cut-off for defining low testosterone; however, total testosterone has been shown to correlate poorly with most questions.164, 165 The use of validated questionnaires is not currently recommended to either define which patients are candidates for testosterone therapy or monitor symptom response in patients on testosterone therapy. Functioning prolactinomas result in hyperprolactinemia, suppressing LH production and leading to low testosterone levels. A systematic review found that varicocele ligation results in significant improvement in testosterone levels in some men, with a mean improvement of approximately 100 ng/dL.|Commanders and medical boards may consider whether the therapy affects physical readiness, cognitive function, mood, or cardiovascular risk. To the extent that this increase in use of testosterone supplementation is based on anticipated improvements in cardiovascular health, sexual function, physical functioning, mood, or cognition, we suggest that it might represent therapy without adequate clinical trial support. Observational studies attributing positive health effects to testosterone may be affected by an increased likelihood of healthier men being prescribed testosterone rather than testosterone improving health. A Medicare-based study identified testosterone exposures and MI outcomes using claims data and matched testosterone-treated with untreated subjects using an empirically derived propensity score and found no increased risk. Men who were treated with testosterone had an increased risk of all-cause mortality, MI, and stroke compared to men who did not use testosterone (HR, 1.29; 95% CI, 1.05–1.58), based on a mean of 27.5 months of follow-up. A Veterans Administration study evaluated men who had undergone coronary angiography and had a total testosterone concentration (presumably plasma) less than 300 ng/dL (10.4 nM).|Ten studies evaluated subjects with HIV; 8 of those studies included subjects with HIV-wasting, 1 included subjects with abdominal obesity, and 1 did not use weight criteria. Twenty studies evaluated subjects described as hypogonadal, with 11 of those evaluating healthy subjects. Physical function was often measured by the 6-minute walk test, the time and number of steps required to walk 25 feet, and the get-up-and-go test, which evaluates the ability to rise from a chair, walk a short distance, and return to sitting. Subjects included both those defined by the authors as hypogonadal and those considered to have normal testosterone concentrations. Ten of 13 of the studies on libido or desire with a Jadad score of 4 or 5 found a benefit.|The unique pharmacokinetic profile of testosterone pellets is due to their crystalline structure, which dissolves slowly in SQ spaces. The manufacturer-recommended dosing of IM testosterone undecanoate is 750 mg administered at weeks 0, 4, and every 10 weeks thereafter. No RCTs have compared the current formulation of IM testosterone undecanoate available in the United States to other therapies. Testosterone undecanoate is the only currently available long-acting injection therapy available as a 750 mg (3 mL) preparation and must be administered in the office under supervision. However, compared to other agents, short-acting injections can result in longer times in the supra-therapeutic and sub-therapeutic ranges, which may impact overall efficacy and rates of adverse events.|It restores the circulating testosterone level to the physiological range. The most common adverse effect with patches is application site reactions, which have been historically reported in up to 60% of patients.181 Other adverse effects include pruritus, application site vesicles, and back pain.431 Compared to topical gels and solutions, the rate of transference is likely minimal. Adverse effects specific to topical preparations include application site reactions (3-16% erythema or rash), and risk of transference. There is no consistent data at this time that demonstrate that one agent achieves higher serum levels than others. Although one objective of meta-analyses is to increase study power to identify significant results, this often results in an amalgamation of studies that may have different primary and secondary endpoints, thereby reducing the reliability of the outcomes. It also highlights that treating clinicians should have specific endpoints for treatment in mind, with regular monitoring of these outcomes to assure that ongoing therapy is warranted and effective.}
The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. These other testosterone delivery methods are just as, if not more effective, and are available on prescription from Male Excel. For those who dislike the idea of self-injecting, testosterone gel and testosterone creams may be a better option.
But you should address symptoms that interfere with your quality of life. Low testosterone may lead to weak bones (osteoporosis) or heart and blood vessel disorders. There’s no one-time fix for low testosterone in men.
Pituitary dysfunction may be a significant cause of testosterone deficiency. A survey of 120 patients who were treated for infertility at the University of Illinois-Chicago found that the incidence of testosterone deficiency was 45% in men with non-obstructive azoospermia, 42.9% in men with oligospermia, and 16.7% in men with obstructive azoospermia.159 There does appear to be a trend towards lower total testosterone and a diagnosis of ED.

Profil Information